- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
CD223 Antibody LAG3/7380 / LAG3 Monoclonal Antibody recognizes lymphocyte activation gene 3 protein, also known as CD223, an inhibitory immune checkpoint receptor encoded by the LAG3 gene. LAG3 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. Its extracellular region contains four immunoglobulin-like domains, while its intracellular tail contains conserved sequences involved in regulating lymphocyte responses. Although structurally related to CD4, LAG3 performs distinct immunoregulatory functions that help control the magnitude and duration of T cell activation.
LAG3 expression is induced following activation of T lymphocytes and is found on subsets of CD4+ and CD8+ T cells, regulatory T cells, and certain natural killer cell populations. The receptor contributes to the suppression of excessive immune activation and supports the maintenance of immune homeostasis. LAG3 recognizes several ligands, including major histocompatibility complex class II molecules and fibrinogen-like protein 1 (FGL1). These interactions participate in complex regulatory mechanisms that influence T cell proliferation, cytokine production, and functional responsiveness.
One of the most extensively investigated aspects of LAG3 biology is its association with T cell exhaustion. During chronic antigen exposure, lymphocytes may progressively lose effector functions while expressing multiple inhibitory receptors. LAG3 is frequently coexpressed with PD-1 in exhausted T cell populations, particularly within tumors and chronic inflammatory environments. This relationship has made LAG3 an important target in cancer immunotherapy, where combined checkpoint inhibition can enhance antitumor immune responses in selected clinical settings.
Beyond cancer, LAG3 contributes to immune regulation during persistent infection and autoimmune disease. Its inhibitory functions can help limit tissue damage caused by prolonged immune stimulation, while excessive checkpoint activity may restrict protective immune responses. The biological effects of LAG3 therefore depend on the balance between immune activation and suppression within a particular tissue environment. Understanding these interactions is important for investigating immune tolerance and the mechanisms governing lymphocyte function.
Clone LAG3/7380 was developed using a recombinant fragment corresponding to a portion of amino acids 300-500 of human LAG3. This region encompasses portions of the extracellular immunoglobulin-like domains and provides a defined immunogen region, although the precise recognized epitope has not been mapped. NSJ Bioreagents offers this CD223 Antibody for research examining immune checkpoint expression, lymphocyte regulation, and LAG3-associated immune responses.
For additional antibodies targeting this inhibitory immune checkpoint receptor, see our LAG3 Antibody F50003.
Optimal dilution of the CD223 Antibody LAG3/7380 / LAG3 Monoclonal Antibody should be determined by the researcher.
A recombinant partial protein sequence (within amino acids 300-500) from the human protein was used as the immunogen for the Lymphocyte activation gene 3 / CD223 antibody.
Aliquot the Lymphocyte activation gene 3 / CD223 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
LAG3 antibody, LAG-3 antibody, Lymphocyte Activation Gene 3 antibody, Lymphocyte Activation Protein 3 antibody, CD223 antigen antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.